ULURU Q4 revenues up

The increase of approximately $796,000 in revenues from the fourth quarter of 2009 compared to the fourth quarter of 2010 was primarily due to increased licensing fees due to the recognition of $751,000 in unamortized licensing fees from the termination of the licensing agreement with Meldex International.

ULURU has reported net loss of $298,005 for the fourth quarter ended 31 December 2010, compared to net loss of $1.7m, or $0.02 loss per diluted share for the comparable period in 2009.

The company has posted operating loss of $288,667, compared to $966,249 for the comparable period in 2009.

For the full year ended 31 December 2010, the company has posted revenue of $1.56m, compare to $667,949, prior year.

ULURU has reported net loss of $5.03m, or $0.06 per diluted share, compared to $9.23m, or $0.14 per diluted share, for the year ago period.

The company has reported $4.14m operating loss, compared to $8.54m for the year ago period.

ULURU president and CEO Kerry Gray said the 2010 results which reflect a significant improvement in our reported loss from 2009 is due principally to the business restructuring that occurred in July 2009.

"The next 6 months will be an exciting period for the company as we anticipate three product launches internationally, the submission of two additional 510(k) applications in the US to expand our Altrazeal product line, significant expansion in Altrazeal revenues, and additional licensing activities," Gray said.